This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study Evaluating Rhapsody Registry in Patients With Depression and Anxiety

This study has been completed.
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer Identifier:
First received: October 17, 2005
Last updated: March 14, 2007
Last verified: March 2007
The purpose of this study is to assess the prevalence of Major Depression and/or Anxiety Disorder in patients consulting the General Practitioner with acute or chronic painful physical symptoms and to identify risk factors.

Pain Depression Anxiety Disorder

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Retrospective
Official Title: An Observational Study on the Presence of Depression and/or Anxiety Disorder in Patients Consulting the General Practitioner With Painful Physical Symptoms in Belgium and Luxemburg.

Resource links provided by NLM:

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Estimated Enrollment: 2560
Study Start Date: November 2005

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Outpatient must be at least 18 years of age
  • Consulting a General Practitioner for painful physical symptoms
  • Written informed consent

Exclusion Criteria:

  • Patient is unable to understand and comply with procedures of the study
  • Patient is unable to complete the patient ratings
  • Patient has an acute pain with an obvious cause
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00241397

  Hide Study Locations
Aarschot, Belgium, 3200
Aiseau-Presles, Belgium, 6250
Anderlues, Belgium, 6150
Andrimont, Belgium, 4821
Angleur, Belgium, 4031
Ans, Belgium, 4430
Anthée, Belgium, 5520
Auvelais, Belgium, 5060
Avelgem, Belgium, 8581
Beauraing, Belgium, 5570
Beernem, Belgium, 8730
Bekegem-Ichtegem, Belgium, 8480
Belgrade, Belgium, 5001
Bertogne, Belgium, 6687
Betekom, Belgium, 3130
Bierges, Belgium, 1301
Binche, Belgium, 7130
Bioul, Belgium, 5537
Braine l'Alleud, Belgium, 1420
Brugge, Belgium, 8000
Brugge, Belgium, 8200
Brussel, Belgium, 1130
Bruxelles, Belgium, 1040
Bruxelles, Belgium, 1050
Bruxelles, Belgium, 1080
Bruxelles, Belgium, 1083
Bruxelles, Belgium, 1090
Bruxelles, Belgium, 1140
Bruxelles, Belgium, 1180
Bruxelles, Belgium, 1200
Charleroi, Belgium, 6000
Ciney, Belgium, 5590
Couillet, Belgium, 6010
Deurne (Antwerpen), Belgium, 2100
Dworp, Belgium, 1653
Eghezée, Belgium, 5310
Eupen, Belgium, 4700
Galmaarden, Belgium, 1570
Goutroux, Belgium, 6030
Grimminge, Belgium, 9506
Hatrival, Belgium, 6870
Hemiksem, Belgium, 2620
Herenthout, Belgium, 2270
Hoboken, Belgium, 2660
Houdeng-Aimeries, Belgium, 7110
Houdeng-Goegnies, Belgium, 7110
Incourt, Belgium, 1315
Itegem, Belgium, 2222
Jabbeke, Belgium, 8490
Jambes, Belgium, 5100
Jodoigne, Belgium, 1370
Kapellen, Belgium, 2950
Kettenis, Belgium, 4701
Klemskerke, Belgium, 8420
Kuurne, Belgium, 8520
Laarne, Belgium, 9270
Lasne, Belgium, 1380
Leuven, Belgium, 3000
Lobbes, Belgium, 6540
Luttre, Belgium, 6238
Melin, Belgium, 1370
Merksem, Belgium, 2170
Monceau-sur-Sambre, Belgium, 6031
Morlanwelz, Belgium, 7140
Moustier S/S, Belgium, 5190
Noorderwijk, Belgium, 2200
Oudenaarde, Belgium, 9700
Ranst, Belgium, 2520
Reves, Belgium, 6312
Rixensart, Belgium, 1330
Romsee, Belgium, 4624
Rotselaar, Belgium, 3110
Ruddervoorde, Belgium, 8020
Sainte-Marie-sur-Semois, Belgium, 6740
Schildewindeke, Belgium, 9860
Schoten, Belgium, 2900
St-Joris Winge, Belgium, 3390
Steenokkerzeel, Belgium, 1820
Waarschoot, Belgium, 9950
Waha, Belgium, 6900
Walem, Belgium, 2800
Wavre, Belgium, 1300
Wetteren, Belgium, 9230
Wevelgem, Belgium, 8560
Wilrijk, Belgium, 2610
Wommelgem, Belgium, 2160
Wondelgem, Belgium, 9032
Wuustwezel-Gooreind, Belgium, 2990
Zelzate, Belgium, 9060
Zemst, Belgium, 1980
Zetrud-Lumay, Belgium, 1370
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Study Director: Medical Monitor, MD Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager For Belgium,
  More Information Identifier: NCT00241397     History of Changes
Other Study ID Numbers: 0600B1-102003
Study First Received: October 17, 2005
Last Updated: March 14, 2007

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
anxiety disorder

Additional relevant MeSH terms:
Depressive Disorder
Anxiety Disorders
Behavioral Symptoms
Mood Disorders
Mental Disorders processed this record on September 21, 2017